ES2059545T3 - Hormonas de glicoproteinas modificadas por mutagenesis dirigida por puntos y metodos de uso de tales hormonas. - Google Patents

Hormonas de glicoproteinas modificadas por mutagenesis dirigida por puntos y metodos de uso de tales hormonas.

Info

Publication number
ES2059545T3
ES2059545T3 ES88312143T ES88312143T ES2059545T3 ES 2059545 T3 ES2059545 T3 ES 2059545T3 ES 88312143 T ES88312143 T ES 88312143T ES 88312143 T ES88312143 T ES 88312143T ES 2059545 T3 ES2059545 T3 ES 2059545T3
Authority
ES
Spain
Prior art keywords
hormones
glycoprotein hormones
directed mutagenesis
glycoprotein
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88312143T
Other languages
English (en)
Other versions
ES2059545T5 (es
Inventor
Scott C Chappel
Edward G Bernstine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Research Systems ARS Holding NV
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22471965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2059545(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Publication of ES2059545T3 publication Critical patent/ES2059545T3/es
Application granted granted Critical
Publication of ES2059545T5 publication Critical patent/ES2059545T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/11—Gonadotropin; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE DESCRIBEN NUEVAS HORMONAS GLICOPROTEINAS CAPACES DE COMPARTIR CON HORMONAS NATURALES PARA LOS SITIOS DE UNION DEL RECEPTOR NORMAL PERO INCAPACES SUSTANCIALMENTE DE EFECTUAR ACTIVIDADES POST RECEPTOR. LAS HORMONAS GLICOPROTEICAS DE LA PRESENTE INVENCION TIENEN CADENAS DE OLEIGOSACARIDOS ELIMINADAS COMO PARA EFECTUAR DISMINUIR LA ACTIVIDAD BIOLOGICA MIENTRAS EL PLASMA (MEDIO - VIDA) REDUCE NO SIGNIFICATIVAMENTE, LAS MOLECULAS DE EFECTIVIFAFES ASI COMO AUMENTADOS COMO UN ANTAGONISTA COMPARADO CON LAS MOLECULAS PRODUCIDAS CONVENCIONALMENTE. LAS HORMONAS GLICOPROTEICAS PREFERIDAS SON OBTENIDAS POR UNTOGENESIS DE SITIO DIRECTO, PARA DEGLICOSILAR SELECTIVAMENTE LA PROTEINA. TAMBIEN SE DESCRIBEN TRATAMIENTOD TERAPEUTICOS QUE COMPRENDEN LA ADMINISTRACION DE HORMONAS GLICOPROTEICAS DE LA PRIMERA INVENCION COMO CON HORMONA ANTAGONISTA.
ES88312143T 1987-12-21 1988-12-21 Hormonas de glicoproteinas modificadas por mutagenesis dirigida por puntos y metodos de uso de tales hormonas. Expired - Lifetime ES2059545T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/136,236 US5260421A (en) 1987-12-21 1987-12-21 Site-directed mutagenesis modified glycoprotein hormones

Publications (2)

Publication Number Publication Date
ES2059545T3 true ES2059545T3 (es) 1994-11-16
ES2059545T5 ES2059545T5 (es) 2000-05-01

Family

ID=22471965

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88312143T Expired - Lifetime ES2059545T5 (es) 1987-12-21 1988-12-21 Hormonas de glicoproteinas modificadas por mutagenesis dirigida por puntos y metodos de uso de tales hormonas.

Country Status (9)

Country Link
US (3) US5260421A (es)
EP (1) EP0322226B2 (es)
JP (1) JP2525048B2 (es)
AT (1) ATE95424T1 (es)
CA (1) CA1341284C (es)
DE (1) DE3884776T3 (es)
ES (1) ES2059545T5 (es)
GR (1) GR3032307T3 (es)
HK (1) HK143395A (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260421A (en) * 1987-12-21 1993-11-09 Applied Research Systems Ars Holding N.V. Site-directed mutagenesis modified glycoprotein hormones
US5635475A (en) * 1987-12-21 1997-06-03 Applied Research Systems Ars Holding N.V. Site-directed mutagenesis modified glycoprotein hormones and methods of use
US5444167A (en) * 1993-07-07 1995-08-22 Wallac Oy Variant luteinizing hormone encoding DNA
EP0739352A1 (en) * 1994-01-20 1996-10-30 Akzo Nobel N.V. New composition of glycoprotein isoforms having follicle stimulating activity
US6238890B1 (en) * 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US5919758A (en) * 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
WO1995032216A1 (en) * 1994-05-25 1995-11-30 University Of Nebraska Board Of Regents Biologically active glycoprotein hormones produced in procaryotic cells
FR2768627B1 (fr) * 1997-09-19 2000-03-24 Agronomique Inst Nat Rech Medicament veterinaire contenant de la choriogonadotropine equine modifiee pour induire l'ovulation chez la jument et stimuler la production de testosterone chez l'etalon
US6927034B2 (en) * 1998-02-03 2005-08-09 The Trustees Of Columbia University In The City Of New York Methods for detecting trophoblast malignancy by HCG assay
US7198954B1 (en) * 1999-02-03 2007-04-03 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by hCG assay
US6500627B1 (en) * 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
WO2001025277A1 (en) * 1999-10-07 2001-04-12 Maxygen Aps Single-chain antagonist polypeptides
US7081446B2 (en) 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
WO2013010840A2 (en) 2011-07-18 2013-01-24 Arts Biologics A/S Long acting biologically active luteinizing hormone (lh) compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
EP0307402B1 (en) * 1986-05-06 1993-08-11 Genetics Institute, Inc. Production of m-csf
US4868119A (en) * 1986-12-11 1989-09-19 Genetics Institute, Inc. Hematopoietic growth factors
US4879227A (en) * 1986-05-06 1989-11-07 Genetics Institute, Inc. Production of a recombinant human colony stimulating factor
JPS63304997A (ja) * 1987-06-08 1988-12-13 Kyowa Hakko Kogyo Co Ltd 魚類の生殖腺刺激ホルモン遺伝子
US5260421A (en) * 1987-12-21 1993-11-09 Applied Research Systems Ars Holding N.V. Site-directed mutagenesis modified glycoprotein hormones
ATE148171T1 (de) * 1989-02-21 1997-02-15 Univ Washington Modifizierte formen von fortpflanzungshormonen

Also Published As

Publication number Publication date
ES2059545T5 (es) 2000-05-01
EP0322226A3 (en) 1990-06-13
HK143395A (en) 1995-09-15
US5352779A (en) 1994-10-04
US5260421A (en) 1993-11-09
GR3032307T3 (en) 2000-04-27
EP0322226A2 (en) 1989-06-28
CA1341284C (en) 2001-08-14
DE3884776T2 (de) 1994-02-10
EP0322226B2 (en) 1999-11-10
DE3884776D1 (de) 1993-11-11
ATE95424T1 (de) 1993-10-15
JP2525048B2 (ja) 1996-08-14
DE3884776T3 (de) 2000-06-21
EP0322226B1 (en) 1993-10-06
US5986068A (en) 1999-11-16
JPH022384A (ja) 1990-01-08

Similar Documents

Publication Publication Date Title
ES2059545T5 (es) Hormonas de glicoproteinas modificadas por mutagenesis dirigida por puntos y metodos de uso de tales hormonas.
NO875299L (no) Insulinpreparat for ikke-paranteral administrasjon.
NO901311D0 (no) Adheson-varianter.
BG62870B1 (bg) Метод за получаване на човешка дезоксирибонуклеаза
PT639979E (pt) Ligando para o receptor c-kit e metodos para a sua utilizacao
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
DE69534723D1 (de) Einzelketten-Gonadotropin
GR3025698T3 (en) NOVEL GABAa RECEPTOR SUBTYPES AND METHODS FOR SCREENING DRUG COMPOUNDS USING IMIDAZOQUINOXALINES AND PYRROLOPYRIMIDINES TO BIND TO GABAa RECEPTOR SUBTYPES.
CA2163118A1 (en) Aurintricaboxylic Acid Fractions and Analogues with Anti-Angiogenic Activity and Methods of Use
DE69033990D1 (de) Glykoprotein-Hormonrezeptor-Moleküle
PT90310A (pt) Processo para a obtencao de preparacoes de adenilato-ciclase
Ulloa-Aguirre et al. Effects of gonadotrophin-releasing hormone, recombinant human activin-A and sex steroid hormones upon the follicle-stimulating isohormones secreted by rat anterior pituitary cells in culture
DE69722809D1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)-antagonisten und inhibitoren der hautmastzell-degranulation
DE69333261D1 (de) KLONIERUNG UND EXPRESSION VON DEM beta APP-C100 REZEPTOR
ZA887365B (en) Adheson variants
Chappel et al. Site-directed mutagenesis modified DNA encoding glycoprotein hormones and methods of use
Raevskaia et al. Selective analgetic effects of angiotensin and bombesin during the action of dental and cutaneous nociceptive irritants
DE19720162A1 (de) Mittel zur Steigerung der Herzkraft

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 322226

Country of ref document: ES